Thermo Fisher Scientific Nivolumab Recombinant Rabbit Monoclonal Antibody (47F6), MonoRab

Applications and Tested Dilution

Product Specifications

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.

Nivolumab is a fully human monoclonal IgG4 antibody approved by the U.S. Food and Drug Administration for the treatment of bladder cancer. It binds to the programmed cell death protein 1 (PD-1) on the surface of activated T cells. Nivolumab functions as a PD-1 inhibitor for targeted immunotherapy.

GenScript MonoRab™ Anti-Nivolumab Antibody (47F6), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Nivolumab.

Target Information

Nivolumab (Opdivo) is a humanized monoclonal antibody approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. It binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in activation of T-cell-mediated immune responses against tumor cells.

For Research Use Only.
Not for use in diagnostic procedures. Not for resale without express authorization.